Pharmaceuticals announced on Friday the Food and Drug Administration has issued a complete response letter regarding the ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Regeneron Pharmaceuticals (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics ...

Swiss pharma giant Novartis (NOVN: VX) has announced a planned $23 billion investment over five years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in ...

Eylea 8 mg (aflibercept 8 mg; in the United States: Eylea HD) is being jointly developed by Bayer and Regeneron. Regeneron maintains exclusive rights to Eylea 2 mg (aflibercept 2 mg) and Eylea HD in ...

Won-ho Joo, Head of the Naval & Special Ship Business Unit at HD Hyundai Heavy Industries, and Brian Schimpf, Co-Founder and CEO of Anduril, sign an MOU for the development and market entry of ...

When approaching the Fire HD 8 – with this version having launched in 2024 – it’s important to ask what you’re getting for your money, because this tablet is not only cheap at full price ...

The results of a large randomized, quality improvement study in the US suggested that integrating large language model (LLM)-generated plain language summaries into ophthalmology notes can improve ...

Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, ...